Stem cell treatment for acute myocardial infarction

Martin‐Rendon, Enca; Brunskill, Susan J; Dorée, Carolyn; Hyde, Chris; Mathur, Anthony; Stanworth, Simon; Watt, Suzanne M.

doi:10.1002/14651858.cd006536.pub2

Cited by 46 publications

(32 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meta-analytic methodology has also been employed to study the genetics of stem cells [27]. Several meta-analyses of cell therapy of solid organ diseases (myocardial infarction) have been published over the last 3 years [28][29][30][31][32]. However, no meta-analysis of cell therapy for neurological disorders on both the preclinical and the clinical level has been conducted.…”

Section: Introductionmentioning

confidence: 99%

Intravenous Route of Cell Delivery for Treatment of Neurological Disorders: A Meta-Analysis of Preclinical Results

Janowski

Walczak

Date

2010

Stem Cells and Development

View full text Add to dashboard Cite

The last decade has been marked by a growing interest in an employment of intravenous cell delivery for treatment of neurological disorders. Numerous preclinical experimental studies have reported functional benefits, and have recently been followed by clinical trials. Some early clinical studies have indicated only modest positive effects, suggesting that the optimal conditions have not been defined yet. Thus, the evaluation of factors that influence outcomes, on the level of the whole population of preclinical studies by advanced statistical analysis, is warranted. PubMed search was conducted from the inception through 2006, and 60 preclinical studies were found and subjected to analysis. Categorical and continuous independent variables (IVs) were extracted. Three distinct outcomes of interest were selected as dependent variables (DVs) and named treatment effects: morphological, behavioral, and molecular, respectively. Mean outcomes, standard deviations (SDs), and animal numbers were retrieved and calculated by individual comparisons of experimental and control groups, based on the Hedges g formula, and were expressed as effect sizes (ESs) and variances. Publication bias and homogeneity were evaluated. The mainspring analyses were performed under a random effect model using Proc Mixed (SAS, version 9.2). A significant heterogeneity and publication bias were found. The ES pooling revealed large treatment effects. Univariate and multivariate meta-regression revealed that cell-related variables explained most of the heterogeneity. Cells retrieved from established lines and genetic modification of cells warrants the highest efficiency, in a dose-dependent manner. The stratified analysis of molecular effect measures revealed that apoptosis inhibition is the strongest brain tissue-positive change induced by cell therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Intravenous Route of Cell Delivery for Treatment of Neurological Disorders: A Meta-Analysis of Preclinical Results

Janowski

Walczak

Date

2010

Stem Cells and Development

View full text Add to dashboard Cite

show abstract

“…Of 13 randomized studies conducted, encompassing 811 participants, the authors of the review stated that more trials are needed to establish efficacy in terms of clinical endpoints such as death. However that authors of the review did observe a consistent improvement in LVEF, as well as trends for decrease in left ventricular end systolic and end diastolic volumes, and infarct size [82]. Two other meta-analysis of randomized trials in the area of bone marrow stem cell infusions also supported the conclusion of safety and mild but statistically significant improvement in LVEF [83,84].…”

Section: Currently Stem Cell Therapy Helps Heart Patients: Just Not Tmentioning

confidence: 91%

Combination stem cell therapy for heart failure

Ichim¹,

Solano²,

Lara³

et al. 2010

International Archives of Medicine

View full text Add to dashboard Cite

Patients with congestive heart failure (CHF) that are not eligible for transplantation have limited therapeutic options. Stem cell therapy such as autologous bone marrow, mobilized peripheral blood, or purified cells thereof has been used clinically since 2001. To date over 1000 patients have received cellular therapy as part of randomized trials, with the general consensus being that a moderate but statistically significant benefit occurs. Therefore, one of the important next steps in the field is optimization. In this paper we discuss three ways to approach this issue: a) increasing stem cell migration to the heart; b) augmenting stem cell activity; and c) combining existing stem cell therapies to recapitulate a "therapeutic niche". We conclude by describing a case report of a heart failure patient treated with a combination stem cell protocol in an attempt to augment beneficial aspects of cord blood CD34 cells and mesenchymal-like stem cells.

show abstract

“…On the other hand, the higher BMSC count may contribute more benefit to LVEF improvement (Fig. 3) [8].…”

Section: Dear Editormentioning

confidence: 99%

“…LVEF improvement according to baseline LVEF level (below or above 45%) and the total ischemic time (before or after 6 h of PCI) [4]. Designed by using data extracted from a metaanalysis of Rendon et al [8].…”

Section: Dear Editormentioning

confidence: 99%